Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GlobalFoundries Inc. Ordinary Shares (GFS) vs Novartis AG (NVS) Price & Performance

GlobalFoundries Inc. Ordinary SharesTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

GlobalFoundries Inc. Ordinary Shares vs Novartis AG — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $50.43 (market cap $27.51B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is far larger — about 9.8× GlobalFoundries Inc. Ordinary Shares's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 0 Days and Novartis AG for 82 Days on average.

GFSNVS
Market Cap
$27.51B$268.57B
Volume
10,416,5721,532,573
Sector
TechnologyHealth
52-Week High
$89.96$168.62
52-Week Low
$32.24$121.80
Typical Hold Time
0 Days82 Days
Enterprise Value
$26.80B$309.89B
Dividend Yield
0.97%3.31%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GlobalFoundries Inc. Ordinary Shares

No Aura AI signal available yet.

Novartis AG

Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.

Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GFS
51% Buy49% Sell
Avg holding period · 0 Days
NVS
100% Buy0% Sell
Avg holding period · 82 Days

Top news

Latest headlines on both assets

About GlobalFoundries Inc. Ordinary Shares

GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.

Read more on GFS →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS →